Abstract Mutations in STXBP1 have recently been identified as a cause of infantile epileptic encephalopathy. The underlying mechanism of the disorder remains unclear and, recently, several case reports have described broad and progressive neurological phenotypes in addition to early-onset epilepsy. Herein, we describe a patient with early-onset epilepsy who subsequently developed a progressive neurological phenotype including parkinsonism in her early teens. A de novo mutation in STXBP1 (c.416C>T, p.(Pro139Leu)) was detected with exome sequencing together with profound impairment of complex I of the mitochondrial respiratory chain on muscle biopsy. These findings implicate a secondary impairment of mitochondrial function in the progressive nature of the disease phenotype.
Introduction
Mutations in STXBP1, a gene involved in the exocytosis of synaptic vesicles, cause an early infantile epileptic encephalopathy with burst suppression (Otahara syndrome) [1] or infantile spasms with non-syndromic encephalopathy [2] . Recent descriptions of STXBP1 mutations in Dravet syndrome [3] and documentation of spasticity and childhood-onset ataxia [4] indicate a broad and progressive disease phenotype.
Here, we report a patient with a novel de novo mutation in STXBP1 who presented with infantile-onset epilepsy and subsequent ataxia and adolescent-onset parkinsonism. Muscle biopsy revealed a profound defect in complex I of the respiratory chain, implicating a mitochondrial pathomechanism.
Case report A full-term neonate born by normal delivery to non-consanguineous parents, presented on day 5 with intermittent generalized seizures. Routine bloods, CT head and lumbar puncture were normal. Her EEG at age 3 weeks showed bilateral multifocal epileptiform discharges imposed on normal background activity, and by age 6 weeks she had a mixture of tonic seizures and intermittent focal seizures of her left arm and right leg. By 4 months of age, her seizures were controlled with phenobarbitone.
Assessment at age 1 year revealed a global developmental delay. At age 6, she was markedly ataxic, and at age 7, she developed head nodding stereotypies. Seizures remained infrequent and an EEG was diffusely abnormal with bifrontal slow waves and a mixture of moderately high-amplitude semirhythmical theta and delta activity. At age 9, she developed dystonic posturing of her legs and a prominent asymmetrical dystonic tremor of her upper limbs. By age 12, this had progressed to an overt extrapyramidal syndrome with a fine resting tremor, cogwheel rigidity and hypomimia. There were additional pyramidal features with global hyperreflexia and upgoing plantars bilaterally. Language and cognition remained severely impaired.
Brain MR images aged 4 and 6 years were normal, as were serum lactate, pyruvate, very long chain fatty acids, phenylalanine, white cell enzymes, alpha-fetoprotein, vitamin E, acanthocytes and karyotype. Molecular analysis for SCA 1, 2, 3, 6, 7 and 17, Friedreich's ataxia, MECP2, DRPLA, POLG, and CDKL5 and screening for ataxia telangiectasia, oculomotor apraxia types 1 and 2 were normal.
Histological and histochemical analyses of a muscle biopsy were normal, but mitochondrial biochemical studies showed a profound defect of respiratory chain complex I activity (<30 % of controls; Fig. 1c ) (methods as described previously [5] ). Extensive molecular analysis including assessment of muscle mitochondrial DNA (mtDNA) levels, a screen for mtDNA rearrangements and point mutations within the whole mitochondrial genome and sequencing of nuclear-encoded structural and assembly factors of complex I yielded normal results.
With further informed parental consent, whole exome sequencing was performed, revealing a heterozygous missense variant in exon 6 of the STXBP1 gene (c.416C>T, p.(Pro139Leu)) not seen in either the 1000genome or ESP6500 public databases, or 300 in-house controls. The p.(Pro139Leu) variant was situated in exon 6 and predicted to be pathogenic by PolyPhen2, SIFT, LRT and MutationTaster software. The mutation was absent in parental blood samples (Fig. 1b) . The same de novo mutation has previously been described in a single case causing an early epileptic encephalopathy, with seizures having ceased at 6-9 months of age and axial hypotonia developing as the only additional neurological sign together with severe mental retardation [6] .
Discussion We report a pathogenic mutation in STXBP1 causing juvenile-onset parkinsonism and associated with a significant impairment of mitochondrial complex I activity in addition to the recognized features of seizures, encephalopathy and ataxia.
It is recognized that a primary defect in mitochondrial function may impair synaptic function [7] ; however, our patient shows the inverse situation may also occur, namely that primary defects in exocytosis may impair mitochondrial function. The mechanism underlying this is unclear, but may be mediated through phospholipase D, as both mitochondrial fusion and synaptic exocytosis, despite being relatively discrete cellular processes, are closely linked through this pathway [8] .
Despite an extensive investigation, our patient did not show any additional non-neurological features associated with mitochondrial disease (sensorineural hearing loss, optic atrophy, diabetes or a cardiomyopathy), further supporting a secondary impairment of mitochondrial function primarily affecting the central nervous system and muscle.
One previous case report has described the case of a 2-yearold male harbouring the c.416C>T mutation [6] . This patient had early-onset seizures and mental retardation, though no evidence of any of the additional neurological symptoms such as ataxia, dystonia and parkinsonism seen in our patient [6] . However, the majority of these symptoms developed after the age of 2, suggesting that complex I impairment may contribute to disease progression. We therefore suggest that treatment aimed at supporting mitochondrial function in patients may be efficacious. Conflict of interest The authors report no disclosures relevant to the manuscript and no conflict of interest.
Consent Informed consent was obtained from all individual participants included in the study.
